Healthcare Jan 02, 2022 02:37 PM (GMT+8) · EqualOcean
On January 1, the new national medical insurance catalogue was officially launched. A total of 74 drugs were added to the catalogue this time, among which domestic innovative drugs have become a well deserved protagonist. It is reported that baizean, a PD-1 monoclonal antibody independently developed by Baiji Shenzhou ® All three new indications (tirelizumab injection) were included in the medical insurance, covering patients with lung cancer and liver cancer. With the implementation of the new medical insurance catalogue, baizean ® Five indications for recurrent and refractory classical Hodgkin's lymphoma, urothelial carcinoma with platinum chemotherapy failure, unresectable local late and advanced lung squamous cell carcinoma, unresectable local late and advanced driver gene wild-type non squamous cell carcinoma, and hepatocellular carcinoma with at least one systemic treatment have been included in the medical insurance, It has become the product with the most indications included in medical insurance among the anti-PD-1 / L1 antibodies on the market. Bai zean ®️ The new price before medical insurance reimbursement is adjusted to 1450 yuan / piece (100mg), with a price decrease of 33.49%. The annual treatment cost is less than 50000 yuan. According to the reimbursement proportion of 80% of medical insurance (subject to the actual reimbursement proportion of various places), the annual treatment cost paid by patients is less than 10000 yuan. Bai zean ® The production and supply of is jointly provided by Boehringer Ingelheim biopharmaceutical industry and Baiji Shenzhou Guangzhou biopharmaceutical industry base. Phase I and phase II plants of Baiji Shenzhou production base have been completed in September 2019 and December 2020 respectively. At present, biological agent production facilities with a capacity of 24000 liters have been built. The planned capacity of phase III plant is 40000 liters, which is expected to be completed by the end of 2022.